CN117295499A - 海鞘素的给药方案 - Google Patents

海鞘素的给药方案 Download PDF

Info

Publication number
CN117295499A
CN117295499A CN202280034530.0A CN202280034530A CN117295499A CN 117295499 A CN117295499 A CN 117295499A CN 202280034530 A CN202280034530 A CN 202280034530A CN 117295499 A CN117295499 A CN 117295499A
Authority
CN
China
Prior art keywords
compound
cancer
dose
use according
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280034530.0A
Other languages
English (en)
Chinese (zh)
Inventor
C·卡哈特
P·拉德利
C·费尔南德兹
A·索图
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of CN117295499A publication Critical patent/CN117295499A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280034530.0A 2021-05-19 2022-05-19 海鞘素的给药方案 Pending CN117295499A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21382455.0 2021-05-19
EP21382455 2021-05-19
PCT/EP2022/063653 WO2022243482A1 (en) 2021-05-19 2022-05-19 Dosage regimens for ecubectedin

Publications (1)

Publication Number Publication Date
CN117295499A true CN117295499A (zh) 2023-12-26

Family

ID=76197383

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280034530.0A Pending CN117295499A (zh) 2021-05-19 2022-05-19 海鞘素的给药方案

Country Status (11)

Country Link
US (1) US20240277705A1 (https=)
EP (1) EP4340841A1 (https=)
JP (1) JP2024521122A (https=)
KR (1) KR20240009437A (https=)
CN (1) CN117295499A (https=)
AU (1) AU2022277799A1 (https=)
CA (1) CA3218171A1 (https=)
IL (1) IL308389A (https=)
MX (1) MX2023013715A (https=)
TW (1) TW202313039A (https=)
WO (1) WO2022243482A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4563149A1 (en) * 2023-11-30 2025-06-04 Pharma Mar, S.A. Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers
WO2025168075A1 (zh) * 2024-02-08 2025-08-14 映恩生物科技(上海)有限公司 海鞘素类化合物及其应用
TW202547489A (zh) 2024-04-30 2025-12-16 西班牙商瑪製藥股份有限公司 化合物ia於包括與阿替利珠單抗的組合療法之癌症的治療中之用途
WO2025228596A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Combination of pm14 and a topoisomerase i inhibitor in the treatment of cancer
WO2025228594A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of ecubectedin in the treatment of cancers including combination therapy with atezolizumab

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE368461T1 (de) * 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
KR102491180B1 (ko) 2017-04-27 2023-01-20 파르마 마르 에스.에이. 항종양 화합물
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Also Published As

Publication number Publication date
JP2024521122A (ja) 2024-05-28
US20240277705A1 (en) 2024-08-22
CA3218171A1 (en) 2022-11-24
EP4340841A1 (en) 2024-03-27
WO2022243482A1 (en) 2022-11-24
MX2023013715A (es) 2024-03-26
KR20240009437A (ko) 2024-01-22
AU2022277799A1 (en) 2023-12-21
TW202313039A (zh) 2023-04-01
IL308389A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
CN117295499A (zh) 海鞘素的给药方案
JP4477303B2 (ja) Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよび化学療法剤を含んでなる併用剤
JP6756609B2 (ja) ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ
TW201919615A (zh) 用於治療tnbc的化合物
TW201817425A (zh) 用於治療非酒精性脂肪肝疾病之醫藥組成物及方法
KR20160101027A (ko) 제약 조합물
JP6643978B2 (ja) 頭頚部がんの処置または予防において使用されるｐｉ３キナーゼ阻害剤とパクリタキセルの組合せ
US20250120970A1 (en) Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug
WO2022179592A1 (zh) 一种急性髓系白血病的联合治疗药物
Basha et al. A Descriptive Study on Adverse Reactions of Chemotherapy and Assessment of Knowledge Score in Cancer Patients
CN120344560A (zh) 用于癌症的新辅助治疗的抗gdf 15抗体
CN117899071A (zh) 一种治疗恶性脑胶质瘤的小分子药物及其应用
TW202608446A (zh) 依維替定（ｅｃｕｂｅｃｔｅｄｉｎ）於包括與阿替利珠單抗的組合療法之癌症的治療中之用途
JP2019513767A (ja) マントル細胞リンパ腫の治療における使用のためのラムシルマブ及びアベマシクリブの組み合わせ療法
HK40093126A (zh) 治疗人的实体瘤的诺氏梭菌
HK40110657A (zh) 用於治疗癌症的cdk4抑制剂
TW201540296A (zh) 使用卡巴利他賽（ｃａｂａｚｉｔａｘｅl）於患有晚期胃腺癌且於先前化療療程已失敗的病患之用途
CN107802833A (zh) 赫赛汀、依维莫司和长春瑞滨的药物组合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination